3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
2
Thrombophilia
1
Rectal Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
EGFR-Mutant Lung Cancer
1
Deglutition Disorders
1
Communication Disorders
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Carcinoma
1
Brain Neoplasms
1
Blood Coagulation Disorders
1
Adenocarcinoma
1
Interventions
Gemcitabine
8
130-nm albumin-bound paclitaxel
5
Albumin-Bound Paclitaxel
4
napabucasin
2
Oxaliplatin
2
MK-4721
2
Leucovorin
2
Fluorouracil
2
Carboplatin
2
tremelimumab
1
irinotecan sucrosofate
1
ensituximab
1
durvalumab
1
contrast agent BR1
1
cc-486
1
Taxes
1
Practice Guidelines as Topic
1
Pancreaticoduodenectomy
1
Paclitaxel
1
PEGPH20
1
Lead
1
Irinotecan
1
Enoxaparin
1
EC regimen
1
Drug Therapy
1
Dexamethasone
1
Cisplatin
1
CP protocol
1
Azacitidine
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Pancreatic Ductal
×
Lead
×
Clear all
NCT01808638
2016-03-11
Atu027-I-02
Silence Therapeutics GmbH
Phase 1/2
Completed
29 enrolled